Hear more about chemotherapy induced peripheral neuropathy, a difficult side effect, and what is being done to help patients in the future.

Richard Paxman welcomes Dr. Maryam Lustberg, MD, MPH, The Ohio State University Comprehensive Cancer Center, Dr Raghav Sundar, Consultant, Department of Haematology-Oncology, National University Cancer Institute, for the next conversation of the series.

Welcoming two world leaders in this field to hear more about chemotherapy induced peripheral neuropathy, a difficult side effect, and what is being done to help patients in the future.

Dr. Maryam Lustberg

Dr Maryam Lustberg is an Associate Professor with Tenure in the Division of Medical Oncology at The Ohio State University, where she specialize in treating patients with breast cancer at The Ohio State’s Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James).

Her research focuses on improving long-term outcomes for breast cancer patients who have developed side effects associated with treatment, and on investigating novel blood-based biomarkers to identify recurrence and treatment toxicity earlier. She joined the Division of Medical Oncology in August 2010 after completing a two-year internal medicine residency at the University of Maryland and a three-year combined medical oncology and breast medical oncology fellowship at Ohio State (2007-2010). She also obtained a Master’s of Public Health (MPH) in Clinical Investigation from Ohio State’s College of Public Health in 2010. She obtained her medical degree from the University of Maryland in 2003.

She serves as the medical director of supportive care for the OSUCCC – James and as director for breast cancer survivorship for The Stefanie Spielman Comprehensive Breast Center. She also chairs the Breast Cancer Survivorship Care Committee. She is physician champion for supportive care services focusing on expanding research, clinical care and programs for this group and serves on the MASCC Board of Directors. She is serving as President Elect of MASCC from 2020 – 2022.

Dr. Raghav Sundaar

Dr Raghav Sundar obtained his medical degree from the Yong Loo Lin School of Medicine, National University of Singapore, where his academic distinctions earned him a place in the Dean’s List and the Thambipillai Silver Medal. He topped the country in the Internal Medicine specialty examination obtaining the Master of Medicine (Internal Medicine) and the Gordon Arthur Ransome Gold Medal in Internal Medicine. He was Chief Resident and Chief Senior Resident during his training at the National University Hospital. He subsequently completed his Medical Oncology Senior Residency at the National University Cancer Institute, Singapore (NCIS). His clinical interest is in gastrointestinal cancers. His research interest lies in early phase drug development, immunotherapy, epigenetics, biomarker discovery, DNA damage repair, and chemotherapy-induced neuropathy. He was awarded the National Medical Research Council Overseas Fellowship Award to undergo fellowship training at the Drug Development Unit, Royal Marsden Hospital, UK. He won the Conquer Cancer Foundation of ASCO Merit Award for his work on developing novel anticancer therapeutics. He holds several grants and has secured over $1,500,000 in grant funding. He has published in high impact peer-reviewed journals including Cancer Discovery, Annals of Oncology and Clinical Cancer Research and designs clinical trials for novel cancer drugs.